Stay updated on STK-012 in Solid Tumors with Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page.

Latest updates to the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe history now includes a new version entry (v3.3.4) and removes v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedAdded a new Revision: v3.3.3 entry; removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check52 days agoChange DetectedSTK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors was replaced with a broader 'Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (SYNERGY-101)'. The update adds or updates sections including Contacts/Locations, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Conditions, Study Description, Oversight, Study Status, and Study Identification.SummaryDifference1%

- Check60 days agoChange DetectedA new revision v3.3.1 was added to the study record history, and the v3.2.0 revision was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check67 days agoChange DetectedThe government funding lapse notice regarding operating status and updates has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check81 days agoChange DetectedThe new screenshot shows the same page with minor visual adjustments to header spacing and table presentation, and no substantive changes to study data or history entries. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to STK-012 in Solid Tumors with Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page.